Improved survival with ipilimumab in patients with metastatic melanoma.

@article{Hodi2010ImprovedSW,
  title={Improved survival with ipilimumab in patients with metastatic melanoma.},
  author={Frank Stephen Hodi and Steven J. O'Day and D F Mcdermott and Robert W Weber and Jeffrey A. Sosman and John B A G Haanen and Rene C. Gonzalez and Caroline Robert and Dirk Schadendorf and Jessica C Hassel and Wallace L Akerley and Alfonsus J M van den Eertwegh and Jose Lutzky and Paul C. Lorigan and Julia M Vaubel and Gerald P. Linette and David R Hogg and Christian H Ottensmeier and C{\'e}l{\`e}ste Lebb{\'e} and Christian Peschel and I. C. Quirt and Joseph I Clark and Jedd D Wolchok and Jeffrey S. Weber and Jason Tian and Michael Jay Yellin and Geoffrey M. Nichol and Axel Hoos and Walter J. Urba},
  journal={The New England journal of medicine},
  year={2010},
  volume={363 8},
  pages={711-23}
}
BACKGROUND An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma. METHODS A total of 676 HLA-A*0201-positive patients with unresectable stage III or IV… CONTINUE READING
Highly Influential
This paper has highly influenced 191 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS